{"product_id":"health-economics-of-dementia-isbn-9780471983767","title":"Health Economics of Dementia","description":"Drugs are being developed to alleviate the symptoms of dementia and different models of care are being tried. This book is a reference work in the subject. It gives a basis of the disease, its epidemiology, care implications, development and use of drugs. It discusses the challenges of obtaining reliable data and reviews the tools used to assess the costs of dementia to date. It also deals with the pharmacoeconomics of dementia.  GENERAL ASPECTS.  \u003cp\u003eClassification and Diagnostics (L. Fratiglioni).\u003c\/p\u003e \u003cp\u003eEpidemiology (L. Fratiglioni).\u003c\/p\u003e \u003cp\u003eSymptomatology: Functional Capacity and Behaviour (H. Brodaty D. Lie).\u003c\/p\u003e \u003cp\u003eCare Options and Service Innovations in Dementia Care (L. Johansson).\u003c\/p\u003e \u003cp\u003eDifferent Ways of Organizing and Financing Health Care (S. H嫡nsson).\u003c\/p\u003e \u003cp\u003eCultural Concepts of Care for the Demented (B. Ineichen).\u003c\/p\u003e \u003cp\u003eInteraction with People Suffering Severe Dementia (A. Norberg).\u003c\/p\u003e \u003cp\u003eDistress and Burden for Family Caregivers (C. Whitlatch).\u003c\/p\u003e \u003cp\u003eHEALTH ECONOMICS APPROACHES TO DEMENTIA.\u003c\/p\u003e \u003cp\u003ePrinciples of Pharmacoeconomics (M. Drummond).\u003c\/p\u003e \u003cp\u003eMethodological Issues in Health Economic Studies of Dementia (G. Karlsson, \u003ci\u003eet al.\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eModeling Disease Progression with Markov Models (F. Sonnenberg E. Leventhal).\u003c\/p\u003e \u003cp\u003eCost of Illness of Dementia (W. Max).\u003c\/p\u003e \u003cp\u003eCosts of Dementia in the Netherlands (M. Koopmanschap, \u003ci\u003eet al.\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eCost of Treatment and Care of Alzheimer's Disease in Germany (J.-M. Schulenburg, \u003ci\u003eet al.\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eCosting Community Care of People with Dementia (M. Knapp R. Wigglesworth).\u003c\/p\u003e \u003cp\u003eIndirect Costs and Costing Informal Care (M. Koopmanschap W. Brouwer).\u003c\/p\u003e \u003cp\u003eThe Resident Assessment Instrument (RAI) and Resource Use in Dementia Care (G. Ljunggren J. Morris).\u003c\/p\u003e \u003cp\u003eCosts of Diagnostic Procedures (S. Gauthier).\u003c\/p\u003e \u003cp\u003eHow Will Japan Cope with the Impending Surge of Dementia? (Y. Arai N. Ikegami).\u003c\/p\u003e \u003cp\u003eDrug Costs in Dementia Care (J. Fastbom M. Giron).\u003c\/p\u003e \u003cp\u003eCosts of Dementia-Specific Care Approaches (A. Wimo, \u003ci\u003eet al.\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eOUTCOME MEASUREMENTS.\u003c\/p\u003e \u003cp\u003eTest Scores in Clinical Trials vs Performance in Real Life: Can Clinical Global Assessments Bridge the Gap? (R. Doody).\u003c\/p\u003e \u003cp\u003eSeverity Scales (B. Reisberg, \u003ci\u003eet al.\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eMeasuring QALYs in Dementia (P. Neumann, \u003ci\u003eet al.\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eAssessing ADL\/IADL in Persons with Dementia (L. Nyg岤).\u003c\/p\u003e \u003cp\u003eAssessment of Cognitive Functioning (O. Almkvist).\u003c\/p\u003e \u003cp\u003eMeasurements of Quality of Life in Dementia (P. Whitehouse).\u003c\/p\u003e \u003cp\u003eAssessment of Behavioral and Psychiatric Symptoms in Patients with Dementia Disorders (S. Eriksson A. Wimo).\u003c\/p\u003e \u003cp\u003eInstruments to Measure the Family Caregiver Burden (M. Grafstr?. Sandman).\u003c\/p\u003e \u003cp\u003ePHARMACOECONOMIC ASPECTS.\u003c\/p\u003e \u003cp\u003eDrug Authorities' Policy on the Assessment of Drugs for Dementia (S. Hill P. McGettigan).\u003c\/p\u003e \u003cp\u003eDesigning Phase III Trials of Anti-dementia Drugs with a View Towards Pharmacoeconomic Considerations (L. Schneider).\u003c\/p\u003e \u003cp\u003eEvaluation of the Healthcare Resource Utilization and Caregiver Time in Anti-dementia Drug Trials (A. Wimo, \u003ci\u003eet al.\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eClinical and Economic Considerations of Anti-Dementia Drug Treatment: Efficacy, Effectiveness, Efficiency (H. Feldman B. Prigent).\u003c\/p\u003e \u003cp\u003eEthical Considerations in Pharmacoeconomic Trials in Dementia (S. Post).\u003c\/p\u003e \u003cp\u003eIssues in Cross-Cultural Assessment of Economic Outcomes in Dementia (E. Witthaus).\u003c\/p\u003e \u003cp\u003eNursing Home Placement and Mortality as Outcomes in Clinical Trials of Anti-Dementia Drugs: Methodological Issues (S. Gracon F. Smith).\u003c\/p\u003e \u003cp\u003eOutcomes Research and Alzheimer's Disease: A Pharmaceutical Industry Perspective (V. Mastey).\u003c\/p\u003e \u003cp\u003eFINAL REMARKS.\u003c\/p\u003e \u003cp\u003eA Proposed Health Economics Research Agenda for Dementia (B. Winblad, \u003ci\u003eet al.\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIndex. \u003c\/p\u003e \"...to the best of my knowledge, this is the only comprehensive review on the health economics of dementia. The book shsould appeal to anyone with a special intrest in dementia, particulalry those involved in clinical trials...\" (\u003ci\u003eInternational Journal of Geriatric Psychiatry\u003c\/i\u003e, Volume 14) \u003cp\u003eAnders Wimo was born in 1952. He's Adjunct Professor in the Department of Neurobiology, care sciences and society at the Karolinska Institutet, Stockholm, Sweden since 2007 and a Family physician in Bergsjo (Halsingland), Sweden since 1991.\u003c\/p\u003e \u003cp\u003ePreviously: Associate Professor, department of Family Medicine, Umea University, Sweden 1995. Clinical lecturer, Primary health Care of Hälsingland, 1999-2000. Researcher, Karolinska Institutet, 1999- 2007. Family physician, Sundsvall, Sweden, 1985-1991.\u003c\/p\u003e  The prevalence of dementia increases greatly with age so, with increasing numbers surviving to old age, Alzheimer?s disease has reached epidemic proportions, and this trend will increase in the future. The disease is therefore having a significant effect on escalating health care costs. Meanwhile, drugs are being developed to alleviate the symptoms of dementia and different models of care are being tried out. All these factors have important cost implications but it has been difficult to draw any consistent conclusions from studies so far. This book will become the standard reference work in the subject. It provides a sound introduction to the disease, its epidemiology, care implications, and the development and use of drugs. It discusses the challenges of obtaining reliable data, and reviews the tools used to assess the outcomes and costs of dementia to date. It also deals with the pharmacoeconomics of the disease, making it essential reading for all those who work with patients with dementia as well as for professionals in the pharmaceutical industry. This volume is: \u003cul\u003e \u003cli\u003eThe first major text of its type to address this important area\u003c\/li\u003e \u003cli\u003eWritten by internationally well-known researchers in this field\u003c\/li\u003e \u003cli\u003eA well-constructed, comprehensive and up-to-date volume providing a wealth of information\u003c\/li\u003e \u003c\/ul\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989350760677,"sku":"NP9780471983767","price":565.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780471983767.jpg?v=1761783772","url":"https:\/\/k12savings.com\/products\/health-economics-of-dementia-isbn-9780471983767","provider":"K12savings","version":"1.0","type":"link"}